Gapping up
In reaction to strong earnings/guidance: ZAGG +13.6% (also authorizes $10 mln for stock repurchase), EIGI +10.3%, TASR +9.9%, MIDD +9.9% (light volume), ANF +8.9%, DEPO +7.5%, RRD +6.5%, PEGA +6.1%, FENG +5.7%, EXAM +4.6%, STV +4.1%, LOW +3.5%, NLY +3.2%, CBI +2.8%, WFT +2.7% (light volume), SLRC +2% (light volume), AMC +1.9% (light volume), SODA+1.6%, TGT +0.9%, SBAC +0.6%, PZZA +0.6% (light volume), NFX +0.5%.
Other news: ANIK +40.7% (FDA Approves MONOVISC, a new single injection treatment for treatment of pain due to osteoarthritis of the knee), PLUG +17.2% (receives multi-site GenKey purchase order from Walmart Stores to roll out its hydrogen fuel cell solution to power electric lift truck fleets at six North America distribution centers), CBAK +11.1% (PLUG sympathy), ARO +7.3% (PE stake speculation), OVTI +4.5% ( announces it is working with Google's Advanced Technology and Projects team to develop vision-based mobile devices, capable of tracking and mapping environments and motion in 3D), YNDX +3.9% (Yandex N.V. and Google announce advertising partnership for real-time bidding), SUNE +3.7% (announced the closing of a non-recourse debt financing arrangement with Deutsche Bank), DYAX +3.6% (announces positive results from phase 1a clinical trial of DX-2930), STM +3.4% (still checking), GALT +2.8% (secures U.S. patent for its proprietary Galectin Inhibitor GR-MD-02 in fatty liver disease), TSLA +2.8% (continued momentum), BBRY +1.2% (Bloomberg discusses comments from BBRY CEO that company will consider BBM spinoff or sale), FCEL +2.4% (PLUG sympathy), SCTY +2.2% (still checking), BUD +1.5% (following ABEV results), CGEN +1.5% (mentioned favorably on Mad Money), QGEN +1.2% ( launches careHPV test in India to expand preventive screening against cervical cancer), FB +0.8% (WhatsApp outage over the weekend might have driven customers to switch to Asian competitor, according to reports), BA +0.4% (awarded ~$2.07 bln Navy contract modification), NQ +0.8% (following late spike on M&A speculation).
Analyst comments: LJPC +28.9% (initiated with Outperform and $27 tgt at Wedbush), PRAN +6.8% ( target raised to $33 from $20.50 at H.C. Wainwright ), LNKD +2.5% (upgraded to Outperform at RBC Capital Mkts; tgt $250), RTEC +2.1% (initiated with a Buy at B. Riley & Co.; tgt $14), KLIC +1.9% (initiated with a Buy at B. Riley & Co)
Other news: ANIK +40.7% (FDA Approves MONOVISC, a new single injection treatment for treatment of pain due to osteoarthritis of the knee), PLUG +17.2% (receives multi-site GenKey purchase order from Walmart Stores to roll out its hydrogen fuel cell solution to power electric lift truck fleets at six North America distribution centers), CBAK +11.1% (PLUG sympathy), ARO +7.3% (PE stake speculation), OVTI +4.5% ( announces it is working with Google's Advanced Technology and Projects team to develop vision-based mobile devices, capable of tracking and mapping environments and motion in 3D), YNDX +3.9% (Yandex N.V. and Google announce advertising partnership for real-time bidding), SUNE +3.7% (announced the closing of a non-recourse debt financing arrangement with Deutsche Bank), DYAX +3.6% (announces positive results from phase 1a clinical trial of DX-2930), STM +3.4% (still checking), GALT +2.8% (secures U.S. patent for its proprietary Galectin Inhibitor GR-MD-02 in fatty liver disease), TSLA +2.8% (continued momentum), BBRY +1.2% (Bloomberg discusses comments from BBRY CEO that company will consider BBM spinoff or sale), FCEL +2.4% (PLUG sympathy), SCTY +2.2% (still checking), BUD +1.5% (following ABEV results), CGEN +1.5% (mentioned favorably on Mad Money), QGEN +1.2% ( launches careHPV test in India to expand preventive screening against cervical cancer), FB +0.8% (WhatsApp outage over the weekend might have driven customers to switch to Asian competitor, according to reports), BA +0.4% (awarded ~$2.07 bln Navy contract modification), NQ +0.8% (following late spike on M&A speculation).
Analyst comments: LJPC +28.9% (initiated with Outperform and $27 tgt at Wedbush), PRAN +6.8% ( target raised to $33 from $20.50 at H.C. Wainwright ), LNKD +2.5% (upgraded to Outperform at RBC Capital Mkts; tgt $250), RTEC +2.1% (initiated with a Buy at B. Riley & Co.; tgt $14), KLIC +1.9% (initiated with a Buy at B. Riley & Co)